Retrobulbar optic neuritis after pamidronate administration in a patient with a history of cutaneous porphyria
Authors:
- 1 January 1997
- journal article
- case report
- Published by Springer Nature in Clinical Rheumatology
- Vol. 16 (1) , 93-95
Abstract
Summary We describe the case of a patient who developed reversible retrobulbar optic neuritis after intravenous pamidronate therapy for established osteoporosis. This possible complication has never been previously reported and, since our patient had a history of porphyria, it suggests that bisphosphonates should be administered cautiously in patients with this disease.Keywords
This publication has 11 references indexed in Scilit:
- Interleukin-6 and the acute phase response during treatment of patients with paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonateJournal of Bone and Mineral Research, 1995
- Pamidronate Disodium and Possible Ocular Adverse Drug ReactionsAmerican Journal of Ophthalmology, 1994
- Two years' effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopauseOsteoporosis International, 1994
- Congenital erythropoietic porphyria: Skeletal manifestations and effect of pamidronate treatmentBone, 1994
- New bisphosphonates in osteoporosisOsteoporosis International, 1993
- Bisphosphonates and iritisThe Lancet, 1993
- Bone metastases and tumor-induced hypercalcemiaCurrent Opinion in Oncology, 1992
- The role of cytokines in the pathogenesis of inflammatory eye diseaseCytokine, 1992
- PamidronateDrugs, 1991
- Ocular Involvement in Cutaneous PorphyriaArchives of Ophthalmology (1950), 1971